Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia / S. A. Ivanova [et al.]

Уровень набора: The World Journal of Biological PsychiatryАльтернативный автор-лицо: Ivanova, S. A., specialist in the field of ecology and life safety, Professor of Tomsk Polytechnic University, doctor of medical sciences, 1964-, Svetlana Aleksandrovna;Osmanova, D. Z., Diana;Freydin, M. V.;Fedorenko, O. Yu., specialist in the field of ecology and life safety, Professor of Tomsk Polytechnic University, doctor of medical sciences, 1973-, Olga Yurievna;Boyko, A. S., Anastasiya Sergeevna;Pozhidaev, I. V., Ivan;Semke, A. V., Arkady Valentinovich;Bokhan, N. A., Nikolay Aleksandrovich;Agarkov, A. A., Aleksey Aleksandrovich;Vilffert, B., Bob;Loonen, A. J. M., AntonКоллективный автор (вторичный): Национальный исследовательский Томский политехнический университет (ТПУ), Институт неразрушающего контроля (ИНК), Кафедра экологии и безопасности жизнедеятельности (ЭБЖ)Язык: английский.Резюме или реферат: Objectives: Hyperprolactinaemia (HPRL) is a classical side effect of antipsychotic drugs primarily attributed to blockade of dopamine D2 subtype receptors in the pituitary gland. Although dopamine is considered the primary factor inhibiting prolactin release, the activity of prolactin-producing lactotrophs is also regulated by the secretagogues thyrotrophin releasing hormone, vasoactive intestinal polypeptide and serotonin (5-hydroxytryptamine; 5-HT). Methods: We describe the association between HPRL and a set of 29 SNPs from 5-HT receptor genes HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, HTR3B and HTR6 in a population of 446 Caucasians (221 males/225 females) with a clinical diagnosis of schizophrenia (according to ICD-10: F20) who were treated with classical and/or atypical antipsychotic drugs. Results: None of the studied autosomal markers were found to be associated with HPRL. However, a significant association was established between various HTR2C polymorphisms and HPRL. Conclusions: This study revealed an association between HPRL and X-chromosome haplotypes comprised of the rs569959 and rs17326429 polymorphisms..Примечания о наличии в документе библиографии/указателя: [References: p. 245-246 (42 tit.)].Аудитория: .Тематика: электронный ресурс | труды учёных ТПУ | polymorphism | antipsychotics | schizophrenia | полиморфизм | шизофрения Ресурсы он-лайн:Щелкните здесь для доступа в онлайн
Тэги из этой библиотеки: Нет тэгов из этой библиотеки для этого заглавия. Авторизуйтесь, чтобы добавить теги.
Оценка
    Средний рейтинг: 0.0 (0 голосов)
Нет реальных экземпляров для этой записи

Title screen

[References: p. 245-246 (42 tit.)]

Objectives: Hyperprolactinaemia (HPRL) is a classical side effect of antipsychotic drugs primarily attributed to blockade of dopamine D2 subtype receptors in the pituitary gland. Although dopamine is considered the primary factor inhibiting prolactin release, the activity of prolactin-producing lactotrophs is also regulated by the secretagogues thyrotrophin releasing hormone, vasoactive intestinal polypeptide and serotonin (5-hydroxytryptamine; 5-HT). Methods: We describe the association between HPRL and a set of 29 SNPs from 5-HT receptor genes HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, HTR3B and HTR6 in a population of 446 Caucasians (221 males/225 females) with a clinical diagnosis of schizophrenia (according to ICD-10: F20) who were treated with classical and/or atypical antipsychotic drugs. Results: None of the studied autosomal markers were found to be associated with HPRL. However, a significant association was established between various HTR2C polymorphisms and HPRL. Conclusions: This study revealed an association between HPRL and X-chromosome haplotypes comprised of the rs569959 and rs17326429 polymorphisms.

Для данного заглавия нет комментариев.

оставить комментарий.